Welcome to our dedicated page for Instil Bio SEC filings (Ticker: TIL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Instil Bio, Inc. filings document formal disclosures for a biotechnology issuer whose recent business focus has included novel therapeutic opportunities and subsidiary-level clinical programs through Axion Bio. Current reports on Form 8-K furnish quarterly and annual financial results, corporate updates, capital resources, restructuring and impairment charges, and material events tied to clinical-development and license-collaboration matters.
Proxy materials describe annual stockholder meeting matters, director elections, board governance, and ratification of the independent registered public accounting firm. Other 8-K disclosures record the change in certifying accountant, including the appointment of RSM US LLP and the replacement of Deloitte & Touche LLP.
Instil Bio, Inc. reported sharply lower operating expenses and losses for the three and six months ended June 30, 2026 as it winds down prior programs and repositions for new in-licensing opportunities. Total operating expenses fell to $5.6 million for the quarter and $12.6 million year-to-date, driven by the discontinuation of AXN-2510 and earlier CoStAR-TIL programs, lower headcount, and reduced development and professional costs.
The company posted a net loss of $4.3 million for the quarter and $8.5 million for the first half, versus much higher losses a year earlier, while generating $4.5 million in rental income from its Tarzana, California facility. Cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million against an $85.6 million fixed-rate term loan secured by the Tarzana facility, due January 2027 with a one-year extension option management expects to exercise. The facility was reclassified from held for sale back to held and used, resulting in a modest $0.2 million net remeasurement loss. Management believes current resources, together with the planned loan extension, will fund operations beyond 2027, but future development will depend on securing new product candidates and potentially additional financing.
Instil Bio, Inc. reported second quarter 2026 results, highlighting a strong cash position and much lower operating costs while it evaluates potential acquisitions and in-licensing opportunities for novel therapeutics. As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $69.9 million, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.
Operating expenses for the quarter fell to $5.6 million from $23.4 million a year earlier, driven by in-process R&D dropping to nil, research and development declining to $0.3 million, and restructuring and impairment charges falling sharply. General and administrative expense also decreased to $5.1 million. Net loss for the quarter narrowed to $4.3 million, or $0.63 per share, compared with $21.4 million, or $3.24 per share, in the prior-year quarter. On a non-GAAP basis, which excludes non-cash stock-based compensation and restructuring and impairment charges, quarterly net loss improved to $3.1 million, or $0.45 per share, versus $19.0 million, or $2.88 per share, a year earlier.
Instil Bio director R. Kent McGaughy Jr received a stock option grant covering 6,500 shares of common stock at an exercise price of $7.93 per share. The option vests in 12 substantially equal monthly installments starting on July 11, 2026, with any unvested portion vesting in full at the next annual stockholder meeting or upon death, Disability, or a Change in Control, subject to continued service.
Instil Bio, Inc. director George Matcham received a grant of stock options covering 6,500 shares of common stock at an exercise price of $7.93 per share. The options were awarded at no purchase price and will vest in 12 substantially equal monthly installments starting on July 11, 2026, subject to his continuous service. Any unvested portion will vest in full at the next annual stockholder meeting, or upon his death, disability, or a change in control, as defined in the company’s 2021 Equity Incentive Plan. Following this grant, he holds 6,500 stock options directly.
Instil Bio director Neil W. Gibson received a stock option grant as compensation. The award covers 6,500 shares of common stock at an exercise price of $7.93 per share and expires on June 10, 2036. The option vests in 12 monthly installments starting July 11, 2026, with accelerated vesting upon the next annual stockholder meeting, death, disability, or a change in control, if he remains in continuous service.
Instil Bio, Inc. director Gwendolyn Binder received a grant of stock options covering 6,500 shares of common stock, with an exercise price of $7.93 per share. These options are compensation, not an open-market purchase, and give her the right to buy shares in the future.
The options vest in 12 substantially equal monthly installments starting on July 11, 2026, as long as she maintains Continuous Service under the company’s 2021 Equity Incentive Plan. Any unvested portion will vest fully at the next annual stockholder meeting, and the options also fully vest upon her death, Disability, or a Change in Control. The options expire on June 10, 2036.
Instil Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 6,781,976 common shares outstanding as of the record date, 5,757,919 shares, or approximately 84.9%, were present or represented by proxy, indicating strong shareholder participation.
Stockholders elected Class II directors George Matcham and Neil Gibson to serve until the 2029 Annual Meeting. Matcham received 3,683,114 votes for and 742,925 withheld, while Gibson received 3,603,901 votes for and 822,138 withheld; each had 1,331,880 broker non-votes. Stockholders also ratified the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 5,750,869 votes for, 6,911 against and 139 abstentions.
Instil Bio, Inc. reported a much smaller net loss of $4.2 million for the quarter ended March 31, 2026, compared with $28.2 million a year earlier, as total operating expenses fell to $7.0 million from $30.6 million following major restructuring and the discontinuation of AXN-2510.
The company held $74.7 million in cash, cash equivalents, restricted cash and marketable securities and generated $2.2 million in rental income from its Tarzana facility, carried at $112.1 million as assets held for sale. Instil has an $85.6 million term loan maturing in January 2027, exceeding its liquid assets, which management identified as an indicator of substantial doubt about its ability to continue as a going concern. Management plans to exercise a contractual option to extend the loan to January 2028 and may refinance, sell the Tarzana facility, or raise additional equity or debt, and concluded these plans alleviate that substantial doubt.
Instil Bio reported first quarter 2026 results showing a much smaller loss and a solid cash position while it evaluates potential acquisitions and in-licensing opportunities for new therapeutics. As of March 31, 2026, the company held about $74.7 million in cash, cash equivalents, restricted cash and marketable securities and expects this to fund its current operating plan beyond 2027.
Net loss for the quarter was $4.2 million, or $0.62 per share, compared with $28.2 million, or $4.32 per share, a year earlier. On a non-GAAP basis, excluding stock-based compensation and restructuring and impairment charges, net loss was $2.2 million, or $0.32 per share, versus $8.6 million, or $1.32 per share.
Operating expenses declined sharply, with research and development at $0.7 million, general and administrative at $5.3 million, and restructuring and impairment charges at $1.0 million, all down significantly from the prior year period. Management highlighted an ongoing strategic shift toward building a focused pipeline through externally sourced assets, while cautioning there is no assurance any transaction will occur.